XTLB - XTL Biopharmaceuticals Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue----
Cost of Revenue--5-
Gross Profit---5-
Operating Expenses
Research Development-43443578
Selling General and Administrative-1,2031,2651,419
Non Recurring----
Total Operating Expenses-1,2461,7132,007
Operating Income or Loss--1,246-1,713-2,007
Income from Continuing Operations
Total Other Income/Expenses Net-465-832-1,615
Earnings Before Interest and Taxes--1,246-1,713-2,007
Interest Expense----6
Income Before Tax--781-2,545-3,622
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops--781-2,545-3,622
Non-recurring Events
Discontinued Operations----691
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income--781-2,545-4,313
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares--781-2,545-4,313